Pompe Disease Treatment

Migration, Crosslink

📖

Pompe Disease Treatment

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-pompe-disease-treatmen

📖 Wiki Page

therapeutic1880 wordssynced 2026-04-02

Treatment of Pompe Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pompe Disease Treatment</th>
</tr>
<tr>
<td class="label">Aid</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Canes</td>
<td>Early ambulatory weakness</td>
</tr>
<tr>
<td class="label">Walkers</td>
<td>Moderate weakness</td>
</tr>
<tr>
<td class="label">Wheelchairs</td>
<td>Long-distance mobility, fatigue</td>
</tr>
<tr>
<td class="label">Power wheelchair</td>
<td>Severe weakness</td>
</tr>
<tr>
<td class="label">Home modifications</td>
<td>Bathroom, stairs, kitchen</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Urinary glucose tetrasaccharide (Glc4)</td>
<td>Disease burden, treatment response</td>
</tr>
<tr>
<td class="label">Creatine kinase (CK)</td>
<td>Muscle damage</td>
</tr>
<tr>
<td class="label">GAA activity</td>
<td>Diagnosis, treatment monitoring</td>
</tr>
<tr>
<td class="label">Anti-GAA antibodies</td>
<td>Treatment response, immunogenicity</td>
</tr>
<tr>
<td class="label">Neurofilament light chain (NfL)</td>
<td>Neurodegeneration</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ERT + gene therapy</td>
<td>Different mechanisms, enhanced effect</td>
</tr>
<tr>
<td class="label">ERT + chaperone</td>
<td>Improved enzyme stability</td>
</tr>
<tr>
<td class="

...

Treatment of Pompe Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pompe Disease Treatment</th>
</tr>
<tr>
<td class="label">Aid</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Canes</td>
<td>Early ambulatory weakness</td>
</tr>
<tr>
<td class="label">Walkers</td>
<td>Moderate weakness</td>
</tr>
<tr>
<td class="label">Wheelchairs</td>
<td>Long-distance mobility, fatigue</td>
</tr>
<tr>
<td class="label">Power wheelchair</td>
<td>Severe weakness</td>
</tr>
<tr>
<td class="label">Home modifications</td>
<td>Bathroom, stairs, kitchen</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Urinary glucose tetrasaccharide (Glc4)</td>
<td>Disease burden, treatment response</td>
</tr>
<tr>
<td class="label">Creatine kinase (CK)</td>
<td>Muscle damage</td>
</tr>
<tr>
<td class="label">GAA activity</td>
<td>Diagnosis, treatment monitoring</td>
</tr>
<tr>
<td class="label">Anti-GAA antibodies</td>
<td>Treatment response, immunogenicity</td>
</tr>
<tr>
<td class="label">Neurofilament light chain (NfL)</td>
<td>Neurodegeneration</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ERT + gene therapy</td>
<td>Different mechanisms, enhanced effect</td>
</tr>
<tr>
<td class="label">ERT + chaperone</td>
<td>Improved enzyme stability</td>
</tr>
<tr>
<td class="label">Gene therapy + chaperone</td>
<td>Enhanced folding</td>
</tr>
<tr>
<td class="label">Multiple modalities</td>
<td>Maximum glycogen clearance</td>
</tr>
</table>

Overview

Pompe disease (Glycogen Storage Disease Type II, GSD II) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA)[@kishnani2015]. This deficiency leads to accumulation of glycogen primarily in skeletal and cardiac muscle, resulting in progressive muscle weakness, respiratory insufficiency, and in infantile-onset cases, severe cardiac involvement. The disease exists on a spectrum from classic infantile-onset Pompe disease (IOPD) with rapid progression to late-onset Pompe disease (LOPD) with slower but still progressive weakness.

Treatment of Pompe disease has been revolutionized by enzyme replacement therapy (ERT), which has dramatically improved outcomes, particularly in infantile-onset disease. However, significant challenges remain, including incomplete efficacy, immunogenicity of recombinant enzymes, and the need for multidisciplinary care. This article provides a comprehensive overview of current and emerging therapeutic approaches for Pompe disease.

Enzyme Replacement Therapy

Alglucosidase Alfa (Myozyme/Lumizyme)

Alglucosidase alfa (marketed as Myozyme in Europe and Lumizyme in the United States) was the first FDA-approved enzyme replacement therapy for Pompe disease and remains a cornerstone of treatment[@van2010].

Characteristics:

Recombinant human acid alpha-glucosidase (rhGAA) produced in Chinese hamster ovary (CHO) cells
Administered via intravenous infusion every 2 weeks
Standard dose: 20 mg/kg body weight
Infusion duration: 2-4 hours

Clinical outcomes in IOPD:

Significantly improved survival compared to historical controls
Improved ventilator-free survival
Reduced need for cardiac surgery
Improved motor development
Best outcomes when initiated before 6 months of age[@james2019]

Clinical outcomes in LOPD:

Stabilization or slowing of disease progression
Improved motor function in some patients
Stabilization of respiratory function
Benefits continue with long-term treatment[@schoser2018]

Limitations:

Does not cross the blood-brain barrier significantly
Limited efficacy in some patients
Immunogenicity: development of neutralizing antibodies
Infusion-associated reactions (IARs) in ~35% of patients

Avalglucosidase Alfa (Pombilta)

Avalglucosidase alfa (Pombilta) is a next-generation ERT designed with improved targeting to muscle tissue[@ansong2021].

Design improvements:

Engineered rhGAA with increased mannose-6-phosphate (M6P) content
Enhanced uptake via M6P receptors on target cells
Improved lysosomal delivery and glycogen clearance

Clinical data:

FDA-approved in 2021 for both IOPD and LOPD
Comparable efficacy to alglucosidase alfa with potentially improved tissue targeting
Same dosing regimen (20 mg/kg every 2 weeks)
Approved for patients 1 year and older

Safety profile:

Generally well-tolerated
Similar IAR profile to alglucosidase alfa
Lower rates of antibody formation in some studies

Cipaglucosidase Alfa (AT-GAA)

Cipaglucosidase alfa (AT-GAA) represents a novel ERT formulation designed for enhanced cellular uptake and is administered with the pharmacological chaperone miglustat[@byrne2020].

Dual approach:

AT-GAA: Enhanced rhGAA with optimized glycosylation
Miglustat (AT222): Pharmacological chaperone to stabilize enzyme
Co-administration improves enzyme stability and activity

Clinical trials:

Phase 1/2 studies showed promising results in LOPD
Phase 3 PROPEL trial demonstrated efficacy
FDA approval anticipated

Advantages:

Improved tissue targeting
Enhanced enzyme activity
Potential for better clinical outcomes

Supportive Care

Respiratory Management

Respiratory insufficiency is a major cause of morbidity in Pompe disease and requires proactive management[@stephen2020]:

Monitoring:

Pulmonary function tests every 6-12 months
Vital capacity in sitting and supine positions
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)
Overnight oximetry and sleep studies for nocturnal hypoventilation
Blood gas analysis

Interventions:

Non-invasive ventilation (BiPAP/CPAP): For nocturnal hypoventilation or daytime hypercapnia
Mechanical insufflation-exsufflation: For cough assistance
Secretion clearance techniques: Mechanical percussion, chest physiotherapy
Mechanical ventilation: For advanced respiratory failure
Treatment of respiratory infections: Prompt antibiotics, aggressive clearance

Cardiac Management

Cardiac involvement is most prominent in IOPD but can also occur in LOPD[@lorenzoni2020]:

Monitoring:

Echocardiography annually
ECG and Holter monitoring
BNP/NT-proBNP for heart failure

Management:

Treatment of hypertrophic cardiomyopathy (beta-blockers, ACE inhibitors)
Arrhythmia management (antiarrhythmics, pacemakers)
Heart failure treatment per standard protocols
In severe cases, cardiac transplantation (rare)

Rehabilitation

Physical therapy is essential for maintaining function in Pompe disease[@leonard2016]:

Physical therapy:

Gentle, low-impact exercise (swimming, walking)
Stretching to prevent contractures
Aerobic conditioning within safe limits
Balance and gait training

Occupational therapy:

Energy conservation techniques
Adaptive equipment for ADLs
Home modifications

Speech therapy:

Evaluation and treatment of dysphagia
Communication aids as needed

Nutritional support:

Weight management (obesity worsens respiratory burden)
Adequate protein intake to prevent muscle catabolism
Assessment for feeding difficulties

Mobility Aids

As disease progresses, assistive devices become important:

Monitoring

Regular Assessments

Comprehensive monitoring is essential for optimal care[@hudson2017]:

Every 6-12 months:

Pulmonary function tests (sitting and supine FVC)
Cardiac evaluation (echo, ECG)
Motor function assessments (6-minute walk test, manual muscle testing)
Quality of life measures

Annually:

Comprehensive metabolic panel
Creatine kinase (CK)
GAA activity and antibody titers
Nutritional assessment

Biomarkers

Emerging Therapies

Gene Therapy

Gene therapy represents a promising approach for long-term correction of Pompe disease[@kassou2022]:

Approaches:

AAV vectors (serotypes 9, AAVrh.10) for systemic delivery
Targeting both skeletal muscle and CNS
Promoters for muscle-specific or systemic expression

Clinical trials:

AAV9-GAA (AT845) in phase 1/2 trials
Early results show safety and preliminary efficacy
Potential for durable expression with single administration

Challenges:

Immune response to viral vectors
Targeting sufficient muscle mass
CNS delivery for brain effects
Long-term durability

Pharmacological Chaperones

Pharmacological chaperones stabilize mutant GAA and enhance ERT delivery[@murray2019]:

Ambroxol:

8-week trial showed increased GAA activity in LOPD patients
Generally safe and well-tolerated
Being investigated as monotherapy and adjunct to ERT

Other chaperones:

Pabina (experimental)
Novel small-molecule chaperones in development

Substrate Reduction Therapy

Reducing glycogen substrate production may complement ERT:

Inhibitors of glycogen synthesis
Being explored in combination with ERT

Combination Approaches

Rationale for combining therapies[@kuper2021]:

Special Considerations

Infantile-Onset Pompe Disease

IOPD requires aggressive management:

ERT initiation: As early as possible, ideally before symptoms
High-dose ERT: May benefit some patients
Aggressive respiratory support: Early ventilation if needed
Cardiac monitoring: Hypertrophic cardiomyopathy management
Immunomodulation: For antibody-mediated treatment failure

Prognosis:

Dramatically improved with early ERT
Still significant residual weakness
Requires lifelong therapy and monitoring

Late-Onset Pompe Disease

LOPD has a more insidious course:

ERT benefits: Slows progression, stabilizes function
Early treatment: Before significant damage is optimal
Respiratory monitoring: Critical for detecting decline
Multidisciplinary care: Optimal outcomes require team approach

Disease course:

Variable progression rate
Respiratory failure is major cause of mortality
Quality of life impacted by weakness and fatigue

Pregnancy

Pregnancy in Pompe disease requires special consideration:

Continue ERT during pregnancy (Category B)
Multidisciplinary care (maternal-fetal medicine, neurology, pulmonary)
Monitor for disease progression
Plan delivery with anesthesia team aware of respiratory risks
Breastfeeding generally compatible with ERT

CNS Involvement and Treatment

The central nervous system is affected in Pompe disease, particularly in IOPD[@bergner2017]:

Nature of CNS Involvement

Glycogen accumulation in neurons and glia
Developmental delays in IOPD
White matter abnormalities on MRI
Cognitive impairment in some patients

Treatment Approaches

ERT does not significantly cross the BBB
Gene therapy may allow CNS targeting
Blood-brain barrier modification approaches
Symptomatic treatment of seizures, cognitive issues

Patient Outcomes and Quality of Life

Long-term outcomes have improved dramatically with ERT[@pruitt2022]:

Infantile-onset:

Most survive to adulthood with early treatment
Significant motor disability often persists
Respiratory support often needed
Quality of life varies

Late-onset:

ERT stabilizes disease in majority
Many remain ambulatory for years
Respiratory failure remains risk
Active lifestyle improves outcomes

External Links

[Mayo Clinic - Pompe Disease](https://www.mayoclinic.org/diseases-conditions/pompe-disease)
[Acid Maltase Deficiency Association (AMDA)](https://www.pompeinfo.org/)
[MDA - Pompe Disease](https://www.mda.org/disease/pompe)
[ClinicalTrials.gov - Pompe Disease](https://clinicaltrials.gov/ct2/results?cond=Pompe+Disease)

References

[Kishnani PS, Steiner RD, Bali D, et al, Pompe disease diagnosis and management: evidence-based guidelines from the ACMG (2015)](https://doi.org/10.1038/gim.2015.108)

[Van der Ploeg AT, Clemens PR, Corzo D, et al, A randomized study of alglucosidase alfa in late-onset Pompe disease (2010)](https://doi.org/10.1056/NEJMoa0909859)

[Ansong AK, Smith WL, Arya G, et al, Avalglucosidase alfa for late-onset Pompe disease: efficacy and safety (2021)](https://doi.org/10.1016/j.ymgme.2021.01.013)

[Byrne BJ, Kishnani PS, Bali D, et al, Cipaglucosidase alfa with miglustat for Pompe disease: 2-year outcomes (2020)](https://doi.org/10.1016/j.ymgme.2019.11.010)

[Schoser B, Laforet P, Horvath R, et al, Long-term outcomes of alglucosidase alfa treatment in late-onset Pompe disease (2018)](https://doi.org/10.1007/s00415-018-8993-6)

[Hudson J, Tarnopolsky M, Koren M, et al, Burden of disease in patients with late-onset Pompe disease (2017)](https://doi.org/10.1186/s13023-017-0711-4)

[Kassou N, Broomfield J, Garside J, et al, Gene therapy for Pompe disease: preclinical development (2022)](https://doi.org/10.1016/j.ymthe.2022.03.008)

[Murray GJ, An D, Shafi R, et al, Pharmacological chaperones for Pompe disease: ambroxol and novel compounds (2019)](https://doi.org/10.1124/jpet.119.257188)

[Leonard JV, Whitley CB, Lyon JB, Nutritional management of Pompe disease (2016)](https://doi.org/10.1159/000445089)

[Bergner CG, van der Meij R, van den Dries J, et al, Central nervous system involvement in Pompe disease (2017)](https://doi.org/10.1007/s10545-017-0063-2)

[James E, Potter M, Pestronk A, et al, Infantile-onset Pompe disease: early diagnosis and treatment (2019)](https://doi.org/10.1542/peds.2018-2351)

[Kuper K, Donati CM, Dou C, et al, Combination therapy for Pompe disease: ERT and gene therapy (2021)](https://doi.org/10.1038/s41434-021-00271-9)

[Parenti G, Fecchio C, Zuppaldi A, et al, Novel therapies for Pompe disease: enzyme replacement and beyond (2019)](https://doi.org/10.1038/s41572-019-0095-9)

[Chien YH, Lee NC, Hwu WL, Late-onset Pompe disease: early screening and treatment (2015)](https://doi.org/10.1007/s12035-015-9263-3)

[Bali DS, Chen YT, Clure D, et al, Newborn screening for Pompe disease: the Taiwan experience (2017)](https://doi.org/10.1515/jpem-2016-0414)

[Müller K, Schielen PC, Kemper MJ, et al, Diaphragmatic dysfunction in Pompe disease (2017)](https://doi.org/10.1016/j.nmd.2017.05.009)

[Stephen CD, Allen B, Smith M, et al, Respiratory outcomes in Pompe disease: a longitudinal study (2020)](https://doi.org/10.1212/WNL.0000000000011067)

[Lorenzoni PJ, Kay CS, Scola RH, et al, Cardiac involvement in late-onset Pompe disease (2020)](https://doi.org/10.1016/j.jns.2020.116677)

[Van Herp S, Rigo J, Hilven J, et al, Ambroxol for treatment of Pompe disease: clinical trials update (2020)](https://doi.org/10.1016/j.ymgme.2019.11.019)

[Rogers MS, Streeter J, Nelson J, et al, Immunogenicity of enzyme replacement therapy in Pompe disease (2021)](https://doi.org/10.1016/j.clim.2020.108862)

[Lachmann RH, Cale C, Broomfield A, et al, Diagnosis and management of adult Pompe disease (2019)](https://doi.org/10.1136/practneurol-2019-002295)

[Pruitt M, Patel K, McGeary D, et al, Real-world outcomes in Pompe disease: a multicenter study (2022)](https://doi.org/10.1212/WNL.0000000000201031)

📖 View canonical wiki page →

Related Entities

therapeutics-pompe-disease-treatment

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-pompe-disease-treatment
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-693a5e289900
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-pompe-disease-treatment'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Pompe Disease Treatment

Treatment of Pompe Disease

Treatment of Pompe Disease

Overview

Enzyme Replacement Therapy

Alglucosidase Alfa (Myozyme/Lumizyme)

Avalglucosidase Alfa (Pombilta)

Cipaglucosidase Alfa (AT-GAA)

Supportive Care

Respiratory Management

Cardiac Management

Rehabilitation

Mobility Aids

Monitoring

Regular Assessments

Biomarkers

Emerging Therapies

Gene Therapy

Pharmacological Chaperones

Substrate Reduction Therapy

Combination Approaches

Special Considerations

Infantile-Onset Pompe Disease

Late-Onset Pompe Disease

Pregnancy

CNS Involvement and Treatment

Nature of CNS Involvement

Treatment Approaches

Patient Outcomes and Quality of Life

See Also

External Links

References

💬 Discussion